Foundayo 14.5 mg: When Should You Move Up?

Foundayo 14.5 mg is the second-highest licensed strength of orforglipron.

By the time a patient reaches this stage, treatment has already been gradually increased through several lower doses.

That makes one question particularly important:

Do you actually need to progress to the maximum 17.2 mg dose?

For many patients, the answer depends entirely on their response and treatment goals.

When can Foundayo increase to 14.5 mg?

The standard Foundayo pathway is:

0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg

Patients should remain on each dose for at least 30 days.

After at least 30 days on 9 mg, a clinician may consider increasing to 14.5 mg once daily, based on treatment response and tolerability.

Why might someone move to 14.5 mg?

A dose increase may be considered if:

• appetite control is no longer sufficient
• hunger has increased
• food noise or cravings have returned
• weight loss remains clinically appropriate but response has slowed significantly
• 9 mg has been well tolerated

However, a slower rate of weight loss alone does not automatically mean treatment needs escalating.

Weight loss commonly slows as body weight falls.

Can I stay on Foundayo 14.5 mg?

Potentially, yes.

There is no requirement for every patient who reaches 14.5 mg to automatically progress to 17.2 mg.

The UK product information states that higher-dose increases are based on treatment response and tolerability.

If 14.5 mg is:

• working effectively
• controlling appetite appropriately
• producing the intended weight outcome
• well tolerated

remaining at that dose may be worth discussing with your clinician.

When might Foundayo 17.2 mg be considered?

17.2 mg is the maximum licensed dose.

It may be considered after at least 30 days on 14.5 mg where:

• additional treatment effect is clinically appropriate
• the current dose is not producing sufficient response
• the patient is tolerating 14.5 mg well

But maximum dose does not mean mandatory dose.

If your goals are already being achieved, an increase may not offer meaningful additional benefit for you.

What about 14.5 mg during maintenance?

This is especially important.

A patient who has already reached their target weight may not have the same clinical goals as someone still actively losing weight.

During maintenance, success may mean:

• keeping weight stable
• controlling hunger without excessive appetite suppression
• eating adequately
• avoiding significant regain
• maintaining treatment comfortably over time

If Foundayo 14.5 mg is achieving those goals, further escalation may not be necessary.

Should I increase if my weight has plateaued?

Not automatically.

A plateau should be viewed in context.

Your clinician may consider:

• how long weight has been stable
• how much weight you have already lost
• whether you are close to your target
• appetite and food intake
• resistance exercise and activity
• sleep
• other medication
• hormonal or medical factors
• side effects

A plateau in someone approaching maintenance may actually be very different from inadequate response early in treatment.

What if I am having side effects on 14.5 mg?

Dose escalation should not be automatic if you are already struggling with tolerability.

Symptoms such as persistent:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• difficulty eating enough

should be reviewed before considering the maximum strength.

Treatment needs to remain sustainable.

How Pharmulous can help

At Pharmulous, we believe that the right dose is more important than the highest dose.

Our approach remains:

Maintenance friendly — achieving your goal weight does not automatically mean treatment stops or continues to escalate.

Flexible — treatment can be reviewed as your response and goals change.

Holistic — we consider weight history, appetite, nutrition, activity, side effects, other medicines and your wider health.

Patient centred — your experience of the medicine and your own goals matter.

Clinically safe — flexibility never overrides safe prescribing or appropriate dose escalation.

Supported — if you are unsure whether 14.5 mg remains appropriate, our clinical team can review your treatment with you.

We do not consider reaching 17.2 mg to be an achievement in itself.

The achievement is finding a treatment plan that safely supports your health and long-term weight-management goals.

The next dose should be used because you need it — not simply because it exists.

Frequently Asked Questions

Is Foundayo 14.5 mg the highest dose?

No. The maximum Foundayo dose is 17.2 mg once daily.

How long should I stay on 14.5 mg?

At least 30 days before any increase to 17.2 mg is considered.

Can I remain on 14.5 mg long term?

Potentially, depending on clinical response, tolerability and your treatment goals.

Should I increase if I'm still losing weight?

Not automatically. If your current dose is achieving the desired result, there may be no reason to increase.

What if I'm maintaining my goal weight on 14.5 mg?

Weight stability may be exactly the desired outcome during maintenance. Your clinician can review whether continuing the current dose remains appropriate.

Key Takeaway

Foundayo 14.5 mg is the step immediately below the maximum dose, but there is no requirement to automatically progress to 17.2 mg.

The decision should depend on:

• appetite
• weight trajectory
• treatment goals
• side effects
• overall tolerability

At Pharmulous, treatment remains flexible, holistic and patient centred, with the aim of finding the lowest effective and well-tolerated dose that safely supports your goals.

References

1. Foundayo 14.5 mg UK Summary of Product Characteristics, electronic Medicines Compendium.
2. Foundayo UK Patient Information Leaflet.
3. Eli Lilly Foundayo dosing and titration information.